BioPharmSignal logoBioPharmSignal

Biotech News

Certara Announces CFO Transition

Certara (CERT)CertaraCompany update

Reaffirms 2026 Guidance RADNOR, Pa., June 17, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, announces that John Gallagher, Chief Financial Officer, has notified the Company of his intent to resign from his office effective as of the end

Related news

CERTCertara2026-08-04 11:00 EST

Certara Reports Second Quarter 2026 Financial Results

CERTCertara2026-07-15 20:15 EST

Certara to Report Second Quarter 2026 Financial Results on August 4th, 2026

View all latest news

Certara

Model-Informed Drug Development Certara provides biosimulation software and technology-enabled services used throughout drug discovery, clinical development and regulatory review. Its tools help predict how medicines behave in different patients and dosing scenarios. Software Portfolio The company's software includes pharmacokinetic,...

Recent company news

CERTCertara2026-08-04 11:00 EST

Certara Reports Second Quarter 2026 Financial Results

CERTCertara2026-07-15 20:15 EST

Certara to Report Second Quarter 2026 Financial Results on August 4th, 2026

CERTCertara2026-07-07 12:00 EST

Certara Accelerates Drug Discovery and Development with NVIDIA BioNeMo Agent Toolkit

CERTCertara2026-06-17 20:30 EST

Certara Announces CFO Transition

CERTCertara2026-05-18 20:15 EST

Certara to Participate in Upcoming Investor Conferences

Stock data

Close
8.13 USD
Market cap
874.27M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States